MDMX Overexpression Prevents p53 Activation by the MDM2 Inhibitor Nutlin
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The p53 tumor suppressor plays a key role in maintaining genomic stability and protection against malignant transformation. MDM2 and MDMX are both p53-binding proteins that regulate p53 stability and activity. Recent development of the MDM2 inhibitor Nutlin 3 has greatly facilitated functional analysis of MDM2-p53 binding. We found that although MDMX is homologous to MDM2 and binds to the same region on p53 N terminus, Nutlin does not disrupt p53-MDMX interaction. The ability of Nutlin to activate p53 is compromised in tumor cells overexpressing MDMX. Combination of Nutlin with MDMX siRNA resulted in synergistic activation of p53 and growth arrest. These results suggest that MDMX is also a valid target for p53 activation in tumor cells. Development of novel compounds that are MDMX-specific or optimized for dual-inhibition of MDM2 and MDMX are necessary to achieve full activation of p53 in tumor cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The IC50s reported in this study are consistent with previous reports showing that MDM2 amplified cancer cell lines (e.g. liposarcoma and osteosarcoma lines) are more sensitive to RG7112 or Nutlin-3 [25–28].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [28]
In the citing paper
“Although nutlin 3a and MI-219 robustly activate p53 in cancer cells with overexpressed MDM2, they do not consistently elicit p53-dependent effects in cancer cells that overexpress MDMX99–102.”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [101]
Citations
Cites
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
MDMX: a novel p53‐binding protein with some functional properties of MDM2.
Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00919.x · Cited by 648
Parant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., & Lozano, G. (2001) · Nature Genetics · doi:10.1038/ng714 · Cited by 517
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53
Linares, L. K., Hengstermann, A., Ciechanover, A., Müller, S., & Scheffner, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2030930100 · Cited by 361
MDM2 interacts with MDMX through their RING finger domains
Tanimura, S., Ohtsuka, S., Mitsui, K., Shirouzu, K., Yoshimura, A., & Ohtsubo, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00254-9 · Cited by 324
Danovi, D., Meulmeester, E., Pasini, D., Migliorini, D., Capra, M., Frenk, R., de Graaf, P., Francoz, S., Gasparini, P., Gobbi, A., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5835-5843.2004 · Cited by 310
MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting
Bond, G., Hu, W., & Levine, A. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332627 · Cited by 308
Stabilization of the MDM2 Oncoprotein by Interaction with the Structurally Related MDMX Protein
Sharp, D. A., Kratowicz, S. A., Sank, M. J., & George, D. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.53.38189 · Cited by 286
Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics
Vassilev, L. T. (2004) · Cell Cycle · doi:10.4161/cc.3.4.801 · Cited by 271
Mutual Dependence of MDM2 and MDMX in Their Functional Inactivation of p53
Gu, J., Kawai, H., Nie, L., Kitao, H., Wiederschain, D., Jochemsen, A. G., Parant, J., Lozano, G., & Yuan, Z.-M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200150200 · Cited by 265
Research works printed but not linked: 2
- Ramos, 2001, Cancer Res., 61, 1839
- Bottger, 1996, Oncogene, 13, 2141
Cited by
Items 201–265 of 265
Fuentes, M., Srivastava, S., Gronenborn, A. M., & LaBaer, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010053 · Cited by 3
Reduction of lymphotoxin beta receptor induces cellular senescence via the MDMX-p53 pathway
Kim, S. Y., Lee, B., Lee, J., Kwak, M. S., Rhee, W. J., Park, I. H., & Shin, J. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02708-1 · Cited by 2
p53-Reactivating Molecules as Research Tools and Anticancer Drugs
Grinkevich, V. V., Warnecke, A., & Selivanova, G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_13 · Cited by 2
Ntwasa, M. M. (2024) · Cells · doi:10.3390/cells13131124 · Cited by 2
Kalathiya, U., Marek-Trzonkowska, N. M., & Padariya, M. (2026) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2026.105554 · Cited by 2
Inhibition of MDM2-p53 feedback loop by various small molecules for potential cancer chemotherapy
Khan, A., & Lu, H. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.6.6196 · Cited by 2
Forte, E., & Luftig, M. (2009) · Infectious Agents and Cancer · doi:10.1186/1750-9378-4-s2-p26 · Cited by 2
Cell death induction in p53-Mdm2 network regulated by p300 and HDAC1 using pinning control
Suárez, O. J., Vega, C. J., Sanchez, E. N., & Santiago, A. E. G. (2019) · International Conference on Electrical Engineering, Computing Science and Automatic Control (CCE) · doi:10.1109/iceee.2019.8884509 · Cited by 2
Manipulation of p53 Protein in Bladder Cancer Treatment
Mansor, S. F. (2021) · IIUM Medical Journal Malaysia · doi:10.31436/imjm.v20i1.1764 · Cited by 2
Targeting p53 Tumor Suppressor for AML Therapy
Kojima, K., & Vassilev, L. T. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1393-0_7 · Cited by 1
Restoring p53 Function: Novel Anticancer Approaches for an Old Foe
(2012) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608054787112010010 · Cited by 1
Yang, Y., Dong, Z., Hu, H., Peng, J., Sheng, Y., Yang, T., Yuan, S., Li, Z., Yang, J., Wells, T., et al. (2019) · The Analyst · doi:10.1039/c9an00350a · Cited by 1
Dynamic behavior of the p53-Mdm2 core module under the action of drug Nutlin and dual delays
Yang, J., Yan, F., & Liu, H. (2021) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2021173 · Cited by 1
Correlación clínico patológica de la ruta de transducción TNF/IL-1/NF-KB en cáncer de próstata
Alcaide, C., & Ramón, J. (2012) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Upstream Targets in the p53 Pathway
McCarthy, A. R., & Laín, S. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_12
The role of TRIM39 in cell cycle and apoptosis
Huang, N.-J. (2013) · DukeSpace (Duke University)
Multiple modes of Mdmx regulation affect p53 activation
Gilkes, D. M. (2008) · Digital Commons - University of South Florida (University of South Florida)
Self-citationTouqan, N. (2014) · UPT. Syiah Kuala University Library (Syiah Kuala University)
Sarek, G. (2010) · Helda - University of Helsinki Institutional Repository
Case Study: Inhibitors of the MDM2‐p53 Protein–Protein Interaction
Shangary, S. K., Bernard, D., & Wang, S. (2010) · Wiley eBooks · doi:10.1002/9780470972137.ch10
Unraveling the signaling network in human cell transformation.
Cipriano, R. (2010) · OhioLink ETD Center (Ohio Library and Information Network)
Sharma, V. K. (2014) · Padua@research (University of Padova)
Induction of p53 Dependent Cellular Senescence Through HdmX Inhibition or YPEL3 Expression
Miller, K. L. (2010) · CORE Scholar (Wright State University)
Chemical biology approaches for the identification of novel p53 regulatory signalling pathways.
Rusilowicz-Jones, E. V. (2013) · ERA
Characterization of the Ubiquitin/Nedd8 E3 ligase activity of the Mdm2/MdmX complex
Singh, R. K. (2007) · Kölner Universitäts PublikationsServer (Universität zu Köln)
Cellular Changes and Effects of Cytokines in the Transformation of Human Mammary Epithelial Cells
Kan, C. E. (2009) · OhioLink ETD Center (Ohio Library and Information Network)
Study of MicroRNA-34a mediated post transcriptional regulation of MDM4
Mandke, P. (2012) · CORE Scholar (Wright State University)
Heminger, K. (2007) · OhioLink ETD Center (Ohio Library and Information Network)
Targeting p53 in cancer: from innovative yeast screening strategies to new drugs
Soares, J. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/056b-7012
Molecular basis for the inhibition of p53 by Mdmx and Mdm2
Czarna, A. (2009) · mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich)
Novel modulation of p53 activity in thyroid cancer
Seed, R. (2013) · University of Birmingham Institutional Research Archive (University of Birmingham)
Development of a Mirror-Image Screening System for Chiral Natural Products
Noguchi, T. (2017) · Springer theses · doi:10.1007/978-981-10-6623-8_2
New approaches to stapled peptides targeting the p53-MDM2 interaction
Saunders, A. W. (2016) · ERA
Analysis of the p53 Regulator MDM2 and the Identification of the Novel p53 Target Gene LRP1
Leslie, P. L. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/mqc4-vn59
Exploring nanobodies interrupting the interaction between p53 and MDM4
Sarıyar, S. (2019) · Sabanci University
Hit-to-lead optimization of pharmaceutical interesting tryptophanol-derived scaffolds
Barcherini, V. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Directed Evolution of Stabilized Peptides with Bacterial Display
Navaratna, T. A. (2020) · Deep Blue (University of Michigan)
A tumormetasztázisban szerepet játszó néhány fehérje vizsgálata NMR spektroszkópiával
Pálfy, G. (2019) · Eötvös Loránd Tudományegyetem · doi:10.15476/elte.2019.142
Smith, J. M. (2014) · UR Research (University of Rochester)
Huang, A., Yang, E., & Kurokawa, M. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101575-1
Huang, A., Yang, E., & Kurokawa, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101575
Pinning Control to Regulate Cellular Response in Cancer for the p53-Mdm2 Genetic Regulatory Network
Suárez, O. J., Vega, C. J., Sanchez, E. N., Chen, G., Santiago, A. E. G., Rodríguez-Jorge, O., Alanís, A. Y., & Hernandez-Vargas, E. A. (2022) · Emergence, complexity and computation · doi:10.1007/978-3-031-04379-6_6
Data from Spontaneous Tumorigenesis in Mice Overexpressing the p53-Negative Regulator Mdm4
Xiong, S., Pant, V., Suh, Y., Pelt, C. S. V., Wang, Y., Valentin-Vega, Y. A., Post, S. M., & Lozano, G. (2023) · doi:10.1158/0008-5472.c.6500723
Data from A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis
Wang, H., Ma, X., Ren, S., Buolamwini, J. K., & Yan, C. (2023) · doi:10.1158/1535-7163.c.6531407
Comparative Analysis of Fluorescent Labeling Techniques for Tracking Canine Amniotic Stem Cells
Parca, A. V., Pieri, N. C. G., Neto, P. F., Bressan, F. F., Ambrósio, C. E., & Martins, D. D. S. (2024) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2023.0286
Exploring the impact of p53 activation on spatio-temporal genome topology
Pasadas, M. C. (2024) · UPCommons institutional repository (Universitat Politècnica de Catalunya) · doi:10.5821/dissertation-2117-422069
Jin, X., Ji, R., Wu, Y.-L. L. C., Wang, J., & Chen, X. (2025) · Nigerian Journal of Clinical Practice · doi:10.4103/njcp.njcp_817_23
Visualization and targeted disruption of protein interactions in living cells
Deng, W. (2014) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.16519
Inhibition of p53 DNA binding function by the MDM2 acidic domain
Cross, B. L. (2011) · Digital Commons - University of South Florida (University of South Florida)
Stefaniak, J. (2019) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-yjok5yaep
Chua, A. J. K., Francesco, V. D., Tesar, B. M., Cathcart, A. M., Bird, G. H., Godes, M., Medha, M. M., Kim, J., Wu, R., Filbin, M. G., et al. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0748
Malhab, L. J. B. (2016) · theses.fr (ABES) · doi:10.70675/a9a79207z0857z4ed5zb207z749cdceb9430
Implication de la voie p53 dans les syndromes d'insuffisance médullaire
Durand, R. (2020) · theses.fr (ABES) · doi:10.70675/6ccc120bz65f7z4c6czabf5z9bea26651b66
Navigating the p53‐MDM2 Landscape: Molecular Insights and Therapeutic Strategies
Mansour, M. A., Hassan, G. S., & Abouzid, K. A. M. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70264
Discovery and evaluation of styrylsulfonyl-methylpyridine derivatives as anticancer agents
Goh, A. W. (2016) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
Lama, R., Xu, C., Galster, S. L., Querol-García, J., Portwood, S., Mavis, C. K., Ruiz, F. M., Martin, D., Wu, J., Giorgi, M. C., et al. (2022) · doi:10.3389/fonc.2022.933446.s005
The role of p53 modulation in correcting aberrant placental apoptosis in pre-eclampsia and IUGR
Sharp, A. (2011) · Research Explorer (The University of Manchester)
Modulation of apoptosis and signalling in cancer cells after treatment with epigenetic modulators
Palani, R. N., & Devi, C. P. A. (2012) · Common Library Network (Der Gemeinsame Bibliotheksverbund)
Sarek, G., & Ojala, P. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1513-9_10
Metadata
- Authors
- Hu, B., Gilkes, D. M., Farooqi, B., Sebti, S. M., & Chen, J.
- Affiliations
- Moffitt Cancer Center (US)
- Corresponding author
- Chen, Jiandong
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-11
- Volume
- 281
- Issue
- 44
- Pages
- 33030-33035
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2052516738
- Cited by
- 236
- References
- 29
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 5 · 2023: 6 · 2022: 4 · 2021: 10 · 2020: 10 · 2019: 10 · 2018: 10 · 2017: 7 · 2016: 17 · 2015: 5 · 2014: 11 · 2013: 14 · 2012: 17
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5082 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- MDMX, MDM2, p53 activation, Nutlin-3, MDM2 inhibitors, p53 stabilization, tumor suppressor, siRNA knockdown, growth arrest
- MeSH terms
- Cell Line, Humans, Imidazoles, Piperazines, Protein Binding, Tumor Suppressor Protein p53, RNA, Small Interfering, Cell Proliferation, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.